RT Journal Article T1 Vasoactive Intestinal Peptide maintains the non-pathogenic profile of human Th17-polarized cells A1 Jimeno Lumeras, Rebeca Gema A1 Leceta Martínez, Javier A1 Martínez Mora, María Del Carmen A1 Gutiérrez Cañas, Irene A1 Carrión Caballo, Mar A1 Pérez García, Selene A1 Garín, Marina I. A1 Mellado, Mario A1 Pérez Gomáriz, Rosa María A1 Juarranz Moratilla, Yasmina AB The cytokine microenvironment modulates CD4 T cell differentiation causing the shift of naïve CD4 T cells into different cell subsets. This process is also regulated by modulators such as VIP, a neuropeptide with known immunomodulatory properties on CD4 T cells that exert this action through specific receptors, VPAC1 and VPAC2. Our results show that the pattern of VIP receptors expression ratio is modified during Th17 differentiation. In this report, we evaluate the capacity of VIP to modulate naïve human cells into Th17 cells in vitro by analyzing their functional phenotype. The presence of VIP maintains the non-pathogenic profile of Th17-polarized cells, increases the proliferation rate and decreases their Th1 potential. VIP induces the up-regulation of the STAT3 gene interaction with the VPAC1 receptor during the onset of Th17 differentiation. Moreover, RORC, RORA and IL-17A genes are up-regulated in the presence of VIP through interaction with VPAC1 and VPAC2 receptors. Interestingly, VIP induces the expression of the IL-23R gene through interaction with the VPAC2 receptor during the expansion phase. This is the first report that describes the differentiation of naïve human T cells to Th17-polarized cells in the presence of VIP and demonstrates how this differentiation regulates the expression of the VIP receptors. PB Springer SN 1559-1166 YR 2014 FD 2014-11 LK https://hdl.handle.net/20.500.14352/33981 UL https://hdl.handle.net/20.500.14352/33981 LA eng NO Jimeno Lumeras, R. G., Leceta Martínez, J., Martínez Mora, M. C. et al. «Vasoactive Intestinal Peptide Maintains the Nonpathogenic Profile of Human Th17-Polarized Cells». Journal of Molecular Neuroscience, vol. 54, n.o 3, noviembre de 2014, pp. 512-25. Crossref, https://doi.org/10.1007/s12031-014-0318-3. NO Instituto de Salud Carlos III NO Comunidad de Madrid NO Unión Europea NO Ministerio de Economía, Comercio y Empresa (España) DS Docta Complutense RD 6 abr 2025